Author Interviews, Depression / 05.03.2023
Ten states including New York and Texas Prescribed no Esketamine or Ketamine to Medicaid patients
Editor's note: This piece discusses suicide. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255. MedicalResearch.com Interview with: Alexia Aguilar Geisinger Commonwealth School of Medicine Scranton, PA MedicalResearch.com: What is the background for this study? Response: Traditional antidepressants like Zoloft and Lexapro have three major drawbacks.
- First, they have a therapeutic lag and take at least a couple weeks to begin to improve mood.
- Second, they do not work very well for many patients with only about one-third experiencing a remission.1
- Third, they carry a Food and Drug Administration black box warning for increasing the risk of suicide in young-adults. There is tremendous enthusiasm for the anesthetic ketamine and esketamine because they overcome all three of these limitations. The brand name of esketamine is Spravato. Spravato received conditional approval from the FDA in March of 2019 as a nasal spray for treatment resistant depression or acute suicidality. The goal of this study was to examine prescriptions for ketamine and esketamine in 2019 and 2020.